Literature DB >> 686870

Neutropenia during treatment of rheumatoid arthritis with levamisole.

G T Williams, S A Johnson, P A Dieppe, E C Huskisson.   

Abstract

Of 60 patients with rheumatoid arthritis treated with levamisole 35% showed a persistent decrease in neutrophil counts from pre-treatment levels and 6 (10%) develped severe neutropenia of less than 1.0 X 10(9)/1. One of these neutropenic patients recoverd without stopping therapy and the other 5 patients recovered rapidly when the drug was withdrawn. In some patients neutropenia recurred on reinstitution of levamisole.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 686870      PMCID: PMC1000246          DOI: 10.1136/ard.37.4.366

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  14 in total

1.  DIAGNOSTIC criteria for rheumatoid arthritis: 1958 revision by a committee of the American Rheumatism Association.

Authors: 
Journal:  Ann Rheum Dis       Date:  1959-03       Impact factor: 19.103

2.  Graphic representation of pain.

Authors:  J Scott; E C Huskisson
Journal:  Pain       Date:  1976-06       Impact factor: 6.961

3.  Immunotherapy with levamisole in rheumatic diseases.

Authors:  M Rosenthal; U Trabert; W Müller
Journal:  Scand J Rheumatol       Date:  1976       Impact factor: 3.641

4.  Recurrent agranulocytosis after levamisole.

Authors:  R Vanholder; W Van Hove
Journal:  Lancet       Date:  1977-01-08       Impact factor: 79.321

5.  Levamisole and agranulocytosis.

Authors:  O Ruuskanen; M Remes; A L Mäkela; H Isomäki; A Toivanen
Journal:  Lancet       Date:  1976-10-30       Impact factor: 79.321

6.  Levamisole and agranolocytosis.

Authors:  R Clara; J Germanes
Journal:  Lancet       Date:  1977-01-01       Impact factor: 79.321

7.  Letter: Levamisole and agranulocytosis.

Authors:  I A Williams
Journal:  Lancet       Date:  1976-05-15       Impact factor: 79.321

8.  Immunostimulant therapy with levamisole for rheumatoid arthritis.

Authors:  E C Huskisson; J Scott; H W Balme; P A Dieppe; J Trapnell; D A Willoughby
Journal:  Lancet       Date:  1976-02-21       Impact factor: 79.321

9.  Levamisole in advanced human breast cancer.

Authors:  A F Rojas; J N Feierstein; E Mickiewicz; H Glait; A J Olivari
Journal:  Lancet       Date:  1976-01-31       Impact factor: 79.321

10.  Double blind crossover trial of levamisole in recurrent aphthous ulceration.

Authors:  T Lehner; J M Wilton; L Ivanyi
Journal:  Lancet       Date:  1976-10-30       Impact factor: 79.321

View more
  4 in total

1.  Cases: Cocaine adulterant linked to neutropenia.

Authors:  Matthew O Wiens; Wai Kon Son; Colin Ross; Michael Hayden; Bruce Carleton
Journal:  CMAJ       Date:  2009-12-07       Impact factor: 8.262

2.  A novel cutaneous vasculitis syndrome induced by levamisole-contaminated cocaine.

Authors:  Rachel L Gross; Jason Brucker; Asena Bahce-Altuntas; Maria A Abadi; Jules Lipoff; David Kotlyar; Peter Barland; Chaim Putterman
Journal:  Clin Rheumatol       Date:  2011-06-25       Impact factor: 2.980

Review 3.  Drug-induced agranulocytosis.

Authors:  H Heimpel
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 Nov-Dec

4.  Cocaine-induced vasculitis: clinical and immunological spectrum.

Authors:  Luis R Espinoza; Rodolfo Perez Alamino
Journal:  Curr Rheumatol Rep       Date:  2012-12       Impact factor: 4.592

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.